GIMEMA
Italy's adult haematology trials group, famous for making acute promyelocytic leukaemia curable without chemotherapy and for chemotherapy-free Philadelphia-positive ALL.
Founded in 1982, GIMEMA coordinates more than 100 Italian haematology centres from Rome. With the German AMLSG it ran APL0406, which showed all-trans retinoic acid plus arsenic trioxide beats chemotherapy in low-to-intermediate risk acute promyelocytic leukaemia, and its LAL2116 D-ALBA trial showed dasatinib followed by blinatumomab can induce deep molecular responses in Ph-positive ALL without cytotoxic chemotherapy. GIMEMA also runs CML, CLL, myeloma and MDS trials and a central laboratory network for molecular monitoring. Its quality-of-life working party pioneered patient-reported outcomes in haematology trials.
- APL0406 (ATRA-arsenic in APL)
- D-ALBA (chemo-free Ph+ ALL)
- CML and CLL trials
- Central molecular monitoring laboratories
Pages like this
not linked directly; found by shared links- TermLeukaemia (tissue type)
Shares Blinatumomab, Imatinib, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia.
- PersonHagop M. Kantarjian
Shares Blinatumomab, Imatinib, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
- TermUndetectable MRD (uMRD / MRD-negative)
Shares Blinatumomab, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing.
- TechnologyMultiparameter flow cytometry MRD
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionAmerican Society of Hematology
Shares European Hematology Association, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing.
- TermFlow cytometry (immunophenotyping)
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, Multiple myeloma, Acute lymphoblastic leukaemia.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma, Acute myeloid leukaemia.
- TermPh-positive ALL
Shares D-ALBA (GIMEMA LAL2116), Blinatumomab, Imatinib, Acute lymphoblastic leukaemia.